key: cord-0305285-6fedz0nc
authors: Rujas, Edurne; Kucharska, Iga; Tan, Yong Zi; Benlekbir, Samir; Cui, Hong; Zhao, Tiantian; Wasney, Gregory A.; Budylowski, Patrick; Guvenc, Furkan; Newton, Jocelyn C.; Sicard, Taylor; Semesi, Anthony; Muthuraman, Krithika; Nouanesengsy, Amy; Prieto, Katherine; Bueler, Stephanie A.; Youssef, Sawsan; Liao-Chan, Sindy; Glanville, Jacob; Christie-Holmes, Natasha; Mubareka, Samira; Gray-Owen, Scott D.; Rubinstein, John L.; Treanor, Bebhinn; Julien, Jean-Philippe
title: Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers
date: 2020-10-16
journal: bioRxiv
DOI: 10.1101/2020.10.15.341636
sha: e004bf4599e5d30565e3fbcd47b82370531ff83e
doc_id: 305285
cord_uid: 6fedz0nc

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes Coronavirus Disease 2019 (COVID-19), has caused a global pandemic. Antibodies are powerful biotherapeutics to fight viral infections; however, discovery of the most potent and broadly acting clones can be lengthy. Here, we used the human apoferritin protomer as a modular subunit to drive oligomerization of antibody fragments and transform antibodies targeting SARS-CoV-2 into exceptionally potent neutralizers. Using this platform, half-maximal inhibitory concentration (IC50) values as low as 9 × 10−14 M were achieved as a result of up to 10,000-fold potency enhancements. Combination of three different antibody specificities and the fragment crystallizable (Fc) domain on a single multivalent molecule conferred the ability to overcome viral sequence variability together with outstanding potency and Ig-like in vivo bioavailability. This MULTi-specific, multi-Affinity antiBODY (Multabody; or MB) platform contributes a new class of medical countermeasures against COVID-19 and an efficient approach to rapidly deploy potent and broadly-acting therapeutics against infectious diseases of global health importance. One Sentence Summary multimerization platform transforms antibodies emerging from discovery screens into potent neutralizers that can overcome SARS-CoV-2 sequence diversity.

The continuous threat to public health from respiratory viruses such as the novel SARS-CoV-2 65 underscores the urgent need to rapidly develop and deploy prophylactic and therapeutic 66 interventions to combat pandemics. Monoclonal antibodies (mAbs) have been used effectively for 67 the treatment of infectious diseases as exemplified by palivizumab for the prevention of respiratory 68 syncytial virus in high-risk infants 1 or Zmapp, mAb114 and REGN-EB3 for the treatment of 69 Receptor binding domain (RBD)-directed mAbs that interfere with binding to angiotensin 73 converting enzyme 2 (ACE2), the receptor for cell entry 22 , are usually associated with high 74 neutralization potencies 11, 12, 14 . 75 mAbs can be isolated by B-cell sorting from infected donors, immunized animals or by identifying 76 binders in pre-assembled libraries. Despite these methodologies being robust and reliable for the 77 discovery of virus-specific mAbs, identification of the best antibody clone can be a lengthy 78 process. For example, RNA viruses have a high mutation rate. Indeed, 198 naturally occurring 79 mutations in the S protein of SARS-CoV-2 have been already registered in the GISAID database 23 . 80

Identification of broadly neutralizing mAbs (bnAbs) that target the most conserved epitopes to 81 overcome viral escape mutations is therefore critical. This approach has been employed to discover 82 bnAbs against human immune deficiency virus 1 (HIV-1) 24 , Influenza 25 , and Ebola 26 . However, 83 their identification required extensive sampling and high-throughput sequencing and consequently 84 several years of research. Hence, there is an unmet need for the development of a platform that 85 cells) (Fig. 3b and Fig. S3a) . The enhanced neutralization potency of the MB was further 176 confirmed with authentic SARS-CoV-2 virus for the mAbs with the highest potency ( Fig. 3c and  177   Fig. S3b) . Retrospectively, all IgGs and MBs were tested for their ability to bind to the S protein 178 and the RBD of SARS-CoV-2 (Fig. S4) . Increased avidity resulted in higher apparent binding 179 affinities with no detectable off-rates against the S protein, most likely due to inter-spike 180 crosslinking that translates into high neutralization potency (Fig. 3b-d and Fig. S4) . Overall Table S1 ). Epitope binning experiments showed that these mAbs target 189 two main sites on the RBD, with one of these bins overlapping with the ACE2 binding site (Fig.  190 4a and Fig. S5 ). Cryo-EM structures of Fab-SARS-CoV-2 S complexes at a global resolution of 191 ~6-7 Å confirmed that mAbs 324, 298, 80 bind overlapping epitopes (Fig. 4b, Fig. S6a -c and 192 Table S2 ). To gain insight into the binding of mAbs targeting the second bin, we obtained the 193 cryo-EM structure of Fab 46 in complex with the RBD at a global resolution of 4.0 Å (Fig. 4c , 194 Table S2) , and the crystal structure of Fabs 298 and 52 as a ternary complex with 195 the RBD at 2.95 Å resolution (Fig. 4d, Fig. S7 and Table S3) . 196

The crystal structure shows that mAb 298 binds almost exclusively to the ACE2 receptor binding 197 motif (RBM) of the RBD (residues 438-506). In fact, out of 16 RBD residues involved in binding 198 mAb 298, 12 are also involved in ACE2-RBD binding (Fig. S7a-c and Table S4 and S5). The 199 RBM is stabilized by 11 hydrogen bonds from heavy and light chain residues of mAb 298. In 200 addition, RBM Phe486 is contacted by 11 mAb 298 residues burying approximately 170 Å 2 (24% 201 of the total buried surface area on RBD) and hence is central to the antibody-antigen interaction 202 ( Fig. S7a and Table S5) . 203

Detailed analysis of the RBD-52 Fab interface reveals that the epitope of mAb 52 is shifted towards 204 the core of the RBD encompassing 20 residues of the RBM and 7 residues in the core domain (Fig.  205 4c, Fig. S7b and Table S6 and S7). In agreement with the competition data, antibody 52 and 206 antibody 46 share a similar binding site, although they approach the RBD with slightly different 207 angles (Fig. 4c-d and Fig. S7d) . Inspection of previously reported structures of RBD-antibody 208 complexes reveal that antibodies 46 and 52 target a site of vulnerability on the SARS-CoV-2 spike 209 that has not been described previously (Fig. 4e) . The epitope targeted by these antibodies is 210 partially occluded by the NTD in the S "closed" conformation, suggesting that the mechanism of 211 action for this new class of antibodies could involve Spike destabilization. Together, these data 212 demonstrate that the enhanced potency observed for the MB platform is associated with mAbs that 213 target both overlapping and distinct epitope bins. 214 215

To explore whether MBs could resist viral escape, we tested the effect of four naturally occurring 217 RBD mutations (L452R, A475V, N439K and V483A) 34 (Fig. 5a) on the binding and neutralization 218 of the seven human mAbs of highest potency (Fig. 5b-c) . In addition, the impact of mutating 219

Asn234, a glycosylation site, to Gln was also assessed because the absence of glycosylation at this 220 site has been previously reported to decrease sensitivity to neutralizing antibodies targeting the 221 RBD 34 . The more infectious PsV variant D614G 35 was also included in the panel. Mutation L452R 222 significantly decreased binding and potency of antibodies 52 and 46, while antibody 298 was 223 sensitive to mutation A475V (Fig. 5b-c) . Deletion of the N-linked glycan at position Asn234 224 increased viral resistance to the majority of the antibodies, especially mAbs 46, 80 and 324, 225 emphasizing the important role of glycans in viral antigenicity (Fig. 5c) . Strikingly, the following 226 mAbs were minimally impacted in their exceptional neutralization potency by any S mutation 227 when present in the MB format: 298, 80, 324, and 236 (Fig. 5d) . Mutation L452R decreased the 228 sensitivity of the 46-MB and 52-MB but in contrast to their parental IgGs, they remained 229 neutralizing against this PsV variant (Fig. 5d) . The more infectious SARS-CoV-2 PsV variant 230 D614G was neutralized with similar potency as the WT PsV for both IgGs and MBs ( Fig. 5c and 231 variants without a significant loss in potency and hence achieved a 100-1000-fold higher potency 234 compared to the corresponding IgG cocktails (Fig. 5e and Fig. S8c-d) . In order to achieve breadth 235 within a single molecule, we next generated tri-specific MBs by combining multimerization 236 subunits displaying three different Fabs in the same MB assembly (Fig. S8b) . Notably, the 237 resulting tri-specific MBs exhibited pan-neutralization while preserving the exceptional 238 neutralization potency of the monospecific versions ( Fig. 5e and Fig. S8c-d) . The most notable 239 increase in potency was for the 298-324-46 combination, where the IgG cocktail neutralized WT 240 SARS-CoV-2 PsV with an ~0.5 µg/mL (3.3 ´ 10 -9 M) IC50, while the tri-specific MB achieved 241 broad neutralization with an exceptional IC50 of ~0.0005 µg/mL (2.2 ´ 10 -13 M). The potency 242 enhancement of MB cocktails and tri-specific MBs in comparison to their corresponding IgG tri-243 specific cocktails was also observed with live replicating SARS-CoV-2 virus (Fig. S8e) . 244 245 Discussion 246

We have developed an antibody-multimerization platform to increase avidity of mAbs targeting 247 SARS-CoV-2. The seven most potent MBs have IC50 values of 0.2 to 2 ng/mL (9 ´ 10 -14 to 9 ´ 10 -248 13 M) against SARS-CoV-2 PsVs and therefore are, to our knowledge, within the most potent 249 antibody-like molecules reported to date against SARS-CoV-2. 250

The MB platform was designed to include key favorable attributes from a developability 251 perspective. First, the ability to augment antibody potency is independent of antibody sequence, 252 format or epitope targeted. The modularity and flexibility of the platform was exemplified by 253 enhancing the potency of a VHH and multiple Fabs that target non-overlapping regions on two 254 SARS-CoV-2 S sub-domains (RBD and NTD). Second, in contrast to other approaches to enhance 255 avidity such as tandem fusions of single chain variable fragments 36,37 , which suffer from low 256 stability, MBs self-assemble into highly stable particles with aggregation temperatures values 257 similar to those of their parental IgGs. Third, alternative multimerization strategies like 258 streptavidin 38 , verotoxin B subunit scaffolds 39 or viral-like nanoparticles 40 face immunogenicity 259 challenges and/or poor bioavailability because of the absence of an Fc fragment and therefore the 260 inability to undergo FcRn-mediated recycling. The light chain of apoferritin is fully human, 261 biologically inactive, has been engineered to include Fc domains, and despite multimerization of 262 >24 Fab/Fc fragments, has a hydrodynamic radius similar to an IgM. As such, a surrogate mouse 263 MB did not elicit anti-drug antibodies in mice, was detectable in the sera for over a week, and has 264 similar biodistribution as its parental IgG. 265 Different increases in neutralization potency were observed for different mAb sequences tested on 266 the MB against SARS-CoV-2. This suggests that the ability of the MB to enhance potency may 267 depend on epitope location on the Spike or the geometry of how the Fabs engage the antigen to 268 achieve neutralization. The fact that 2 out of 20 SARS-CoV-2 RBD binders were not rescued by 269 the MB platform also suggests limitations based on mAb sequences and binding properties. 270

Nevertheless, the capacity of the MB to transform avidity into neutralization potency across a 271 range of epitope specificities on the SARS-CoV-2 Spike highlights the potential for using this 272 technology broadly. It will be interesting to explore the potency-enhancement capacity of the MB 273 platform against viruses with low surface spike density like HIV 41 , or against other targets like the 274 tumor necrosis factor receptor superfamily, where bivalency of conventional antibodies limits their 275 efficient activation 42 . 276

Virus escape can arise in response to selective pressure from treatments or during natural selection. 277

A conventional approach to combat escape mutants is the use of antibody cocktails targeting 278 different epitopes. MBs showed a lower susceptibility to S mutations in comparison to their 279 parental IgGs, presumably because the loss in affinity was compensated by enhanced binding 280 avidity. Hence, when used in cocktails, the MB overcame viral sequence variability with 281 exceptional potency. In addition, the split MB design allows combination of multiple antibody 282 specificities within a single multimerized molecule resulting in similar potency and breadth as the 283 MB cocktails. To our knowledge, these MBs represent the first tri-specifics described against 284 SARS-CoV-2. Multi-specificity within the same particle could offer additional advantages such as 285 intra-S avidity and synergy for the right combination of mAbs, setting the stage for further 286 investigation of different combinations of mAb specificities on the MB. 287

Overall, the MB platform provides a tool to surpass antibody affinity limits and generate broad 288 and potent neutralizing molecules without the need for extensive antibody discovery or 289 engineering efforts. This platform will accelerate the timeline from discovery to development of 290 Correspondence to: jean-philippe.julien@sickkids.ca

Materials and Methods Figs. S1 to S8 Tables S1 to S7

Genes encoding VHH-human apoferritin fusion, Fc fusions, Fabs, IgG, and RBD mutants were 

3 μL of Multabody at a concentration approximately of 0.02 mg/mL was placed on the surface of a carbon-coated copper grid that had previously been glow-discharged in air for 15 sec, allowed to adsorb for 30 s, and stained with 3 μL of 2% uranyl formate. Excess stain was removed immediately from the grid using Whatman No. 1 filter paper and an additional 3 μL of 2% uranyl formate was added for 20 s. Grids were imaged with a FEI Tecnai T20 electron microscope operating at 200 kV and equipped with an Orius charge-coupled device (CCD) camera (Gatan Inc).

Direct binding kinetics measurements were conducted using an Octet RED96 BLI system (Sartorius ForteBio) in PBS pH 7.4, 0.01% BSA and 0.002% Tween at 25º C. His-tagged RBD or SARS-CoV-2 Spike protein was loaded onto Ni-NTA (NTA) biosensors (Sartorius ForteBio) to reach a BLI signal response of 0.8 nm. Association rates were measured by transferring the loaded biosensors to wells containing a 2-fold dilution series from 250 to 16 nM (Fabs), 125 to 4 nM (IgG), and 16 to 0.5 nM (MB). Dissociation rates were measured by dipping the biosensors into buffer-containing wells. The duration of each of these two steps was 180 s. Fc characterization in the split Multabody design was assessed by measuring binding to hFcγRI and hFcRn. To probe the theoretical capacity of the Multabodies to undergo endosomal recycling, binding to the hFcRn b2-microglobulin complex was measured at physiological (7.5) and endosomal (5.6) pH.

Competition assays were performed in a two-step binding process. Ni-NTA biosensors preloaded with His-tagged RBD were first dipped into wells containing the primary antibody at 50 μg/mL for 180 s. After a 30 s baseline period, the sensors were dipped into wells containing the second antibody at 50 μg/ml for an additional 300 s.

The hydrodynamic radius (Rh) of the Multabody was determined by dynamic light scattering (DLS) using a DynaPro Plate Reader III (Wyatt Technology). 20 μL of the Multabody at a concentration of 1 mg/mL was added to a 384-well black, clear bottom plate (Corning) and measured at a fixed temperature of 25º C with a duration of 5 s per read. Particle size determination and polydispersity were obtained from the accumulation of 5 reads using the Dynamics software (Wyatt Technology).

Aggregation temperature (Tagg) of the Multabodies and parental IgGs were determined using a UNit instrument (Unchained Labs). Samples were concentrated to 1.0 mg/mL and subjected to a thermal ramp from 25 to 95° C with 1° C increments. T agg was determined as the temperature at which 50% increase in the static light scattering at a 266 nm wavelength relative to baseline was observed (i.e. the maximum value of the differential curve). The average and the standard error of two independent measurements were calculated using the UNit analysis software. Selected phages were acid eluted from the beads and neutralized using Tris-HCl pH 7.9 (Teknova).

ER2738 cells were infected with the neutralized phage pools at OD600=0.5 at a 1:10 ratio and after 40 min incubation at 37º C and 100 rpm, the phage pools were centrifuged and incubated on agar with antibiotic selection overnight at 30º C. The rescued phages were precipitated by PEG and subjected to three additional rounds of soluble-phase automated panning. PBST/1% BSA buffer and/or PBS/1% BSA was used in the de-selection, washes and selection rounds.

Anti-SARS-CoV-2 RBD scFvs selected from phage display were expressed and screened using high-throughput surface plasmon resonance (SPR) on Carterra LSA Array SPR instrument 

SARS-CoV-2 pseudotyped viruses (PsV) were generated using an HIV-based lentiviral system as 

VeroE6 cells were seeded in a 96F plate at a concentration of 30,000/well in DMEM supplemented with 100U Penicillin, 100U Streptomycin and 10% FBS. Cells were allowed to adhere to the plate and rest overnight. After 24 h, 5-fold serial dilutions of the IgG and MB samples were prepared in DMEM supplemented with 100U Penicillin and 100U Streptomycin in a 96R plate in quadruplicates (25 uL/well). 25 uL of SARS-CoV-2/SB2-P4-PB 45 Clone 1 was added to each well at 100TCID/well and incubated for 1 h at 37 °C with shaking every 15 min. After co-culturing, the media from the VeroE6 plate was removed, and 50 uL antibody-virus sample was used to inoculate VeroE6 cells in quadruplicates for 1 h at 37 °C, 5% CO2, shaking every 15 min. After 1 h inoculation, the inoculum was removed and 200 uL of fresh DMEM supplemented with 100U Penicillin, 100U Streptomycin and 2% FBS was added to each well. The plates were further incubated for 5 days. The cytopathic effect (CPE) was monitored and PRISM was used to calculate IC50 values. Three biological replicates with four technical replicates each were performed.

100 µg of Spike trimer was mixed with 2x molar excess of Fab 80, 298 or 324 in 20 mM HEPES pH 7.0, 150 mM NaCl. Proteins were crosslinked by addition of 0.075% (v/v) glutaraldehyde (Sigma Aldrich) and incubated at room temperature for 120 min. Complexes were purified via size exclusion chromatography (Superose6 Increase 10/300 GL, GE Healthcare), concentrated to 0.5 mg/mL and directly used for cryo-EM grid preparation. 

3 µl of sample was deposited on holey gold grids prepared in-house 51 , which were glow-discharged in air for 15 s with a PELCO easiGlow (Ted Pella) before use. Sample was blotted for 6 s with a modified FEI Mark III Vitrobot (maintained at 4º C and 100% humidity) using an offset of -5, and subsequently plunge-frozen in a mixture of liquid ethane and propane. Data was acquired at 300 kV with a Thermo Fisher Scientific Titan Krios G3 electron microscope and prototype Falcon 4 camera operating in electron counting mode at 250 frames/s. Movies were collected for 9.6 s with 29 exposure fractions, a camera exposure rate of ~5 e -/pix/s, and total specimen exposure of ~44 e -/Å 2 . No objective aperture was used. The pixel size was calibrated at 1.03 Å/pixel from a gold diffraction standard. The microscope was automated with the EPU software package and data collection was monitored with cryoSPARC Live 52 .

To overcome preferred orientation encountered with some of the samples, tilted data collection was employed 53 MotionCorr 54,55 was used. Micrographs were then imported into cryoSPARC and patch CTF estimation was performed. Templates generated from 2D classification during the cryoSPARC Live session were used for template selection of particles. 2D classification was used to remove junk particle images, resulting in a dataset of 80,951 particle images for the Spike-Fab 80 complex, 203,138 particle images for the Spike-Fab 298 complex, 64,365 particle images for the Spike-Fab 324 complex, and 2,143,629 particle images for the RBD-Fab 46 complex. Multiple rounds of multi-class ab initio refinement were used to clean-up the particle image stacks, and homogeneous refinement was used to obtain consensus structures. For tilted particles, particle polishing was done within Relion at this stage and re-imported back into cryoSPARC. For the Spike-Fab complexes, extensive flexibility was observed. 3D variability analysis was performed 56 and together with heterogeneous refinement used to classify out the different states present. Non-uniform refinement was then performed on the final set of particle images 57 . For the RBD-Fab 46 complex, cryoSPARC ab initio refinement with three classes was used iteratively to clean up the particle image stack.

Thereafter, the particle image stack with refined Euler angles was brought into cisTEM for reconstruction 58 to produce a 4.0 Å resolution map. Transfer of data between Relion and cryoSPARC was done with pyem 59 . . Tagg values are calculated from the maximum of the differential curves (light red) and indicated with yellow lines. 5 10 -4 10 -3 10 -2 10 -1 10 0 10 1 Epitope binning. mAb binding competition experiments to His-tagged RBD as measured by biolayer interferometry (BLI). 50 µg/ml of mAb 1 was incubated for 3 min followed by incubation with 50 µg/ml of mAb 2 for 5 min. 

Algorithms for rapid unsupervised cryo-EM structure determination

Addressing preferred specimen orientation in single-particle cryo-EMthrough tilting

New tools for automated high-resolution cryo-EM structure determination in RELION-3

RELION: Implementation of a Bayesian approach to cryo-EM structure determination

3D Variability Analysis: Directly resolving continuous flexibility and discrete heterogeneity from single particle cryo-EM images

Non-uniform refinement: Adaptive regularization improves single particle cryo-EM reconstruction

CisTEM, user-friendly software for single-particle image processing

UCSF pyem v0. 5

vdW: van der Waals interaction (5.0 Å cut-off) HB: hydrogen bond (3.8 Å cut-off) SB: salt bridge

GlnGlyThrGly 28 vdW H-Trp50, H-Thr57, H-Asp58 486PheCys